ALDOB is a prognostic biomarker and a potential immunotherapy target for clear cell renal cell carcinoma.

ABSTRACT:

Background

Aldolase B (ALDOB), functioning as a glycolytic enzyme, exhibits a controversial role in malignancies and demonstrates dual potential as both a tumor suppressor and cancer-promoting enzyme. Nevertheless, it is still uncertain if there is a relationship between ALDOB levels, prognosis, and tumor-infiltrating lymphocytes in clear cell renal cell carcinoma (ccRCC).

Objective

This study aims to investigate the prognostic significance of ALDOB in ccRCC and its potential association with clinicopathological features and tumor immune microenvironment. By integrating multi-database bioinformatics analysis and experimental validation, we seek to elucidate the role of ALDOB in ccRCC progression and its potential as a predictive biomarker.

Meth

SUBMITTER: Xu W 

PROVIDER: S-EPMC12369605 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature